Role of SHIP1 in cancer and mucosal inflammation

Annals of the New York Academy of Sciences

Volumn 1280, Issue 1, 2013, Pages 6-10

  Fernandes, Sandra ^a   Iyer, Sonia ^a   Kerr, William G ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Cancer; Caspase 8; Crohn's disease; SHIP1; T cell

Indexed keywords

PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN SH 2 CONTAINING INOSITOL 5'POLYPHOSPHATASE 1; PROTEIN SH2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL SURVIVAL; CROHN DISEASE; EFFECTOR CELL; ENZYME ACTIVITY; FLOW CYTOMETRY; GERM LINE; HUMAN; ILEUM; INTRACELLULAR SIGNALING; MUCOSA INFLAMMATION; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN TARGETING; TUMOR XENOGRAFT;

EID: 84875648250     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12038     Document Type: Article

References (17)

1. Kerr, W.G. Inhibitor and activator: dual functions for SHIP in immunity and cancer. Ann. N.Y. Acad. Sci.
2. Hazen, A.L. et al. 2009. SHIP is required for a functional hematopoietic stem cell niche. Blood 113: 2924-2933.
3. Ming-Lum, A. et al. 2012. A pleckstrin homology-related domain in SHIP1 mediates membrane localization during Fcgamma receptor-induced phagocytosis. FASEB J. 26: 3163-3177.
4. Ong, C.J. et al. 2007. Small-molecule agonists of SHIP1 inhibit the phosphoinositide 3-kinase pathway in hematopoietic cells. Blood 110: 1942-1949.
5. Zhang, J., S.F. Walk, K.S. Ravichandran & J.C. Garrison. 2009. Regulation of the Src homology 2 domain-containing inositol 5′-phosphatase (SHIP1) by the cyclic AMP-dependent protein kinase. J. Biol. Chem. 284: 20070-20078.
6. Wahle, J.A. et al. 2007. Inappropriate recruitment and activity by the Src homology region 2 domain-containing phosphatase 1 (SHP1) is responsible for receptor dominance in the SHIP-deficient NK cell. J. Immunol. 179: 8009-8015.
7. Peng, Q. et al. TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1. Sci. Signal. 3: ra38.
8. Brooks, R. et al. 2010. SHIP1 inhibition increases immunoregulatory capacity and triggers apoptosis of hematopoietic cancer cells. J. Immunol. 184: 3582-3589.
9. Fuhler, G.M. et al. 2012. Therapeutic potential of SH2 domain-containing inositol-5′-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer. Mol. Med. 18: 65-75.
10. Gewinner, C. et al. 2009. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 16: 115-125.
11. Charlier, E. et al. 2010. SHIP-1 inhibits CD95/APO-1/Fas-induced apoptosis in primary T lymphocytes and T leukemic cells by promoting CD95 glycosylation independently of its phosphatase activity. Leukemia 24: 821-832.
12. Helgason, C.D. et al. 1998. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Develop. 12: 1610-1620.
13. Kerr, W.G., M.Y. Park, M. Maubert & R.W. Engelman SHIP deficiency causes Crohn's disease-like ileitis. Gut 60: 177-188.
14. Ghansah, T. et al. 2004. Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses. J. Immunol. 173: 7324-7330.
15. Liu, Q. et al. 1999. SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival. Genes Develop. 13: 786-791.
16. Wang, J.W. et al. 2002. Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation. Science 295: 2094-2097.
17. Karlsson, M.C. et al. 2003. Macrophages control the retention and trafficking of B lymphocytes in the splenic marginal zone. J. Exp. Med. 198: 333-340.